BeOne Medicines (BEIGF) Cash from Operations Growth (3y) (2018 - 2026)
Powered by 
Analysis
BeOne Medicines (BEIGF) Cash from Operations Growth (3y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.95 Bn | 625.20 Bn | 17.26 Bn | 27.24% |
| 2 | AbbVie | 441.39 Bn | 434.82 Bn | 12.70 Bn | -18.38% |
| 3 | Merck | 366.72 Bn | 359.58 Bn | 12.21 Bn | 13.18% |
| 4 | Novartis Ag | 266.68 Bn | 258.99 Bn | 11.24 Bn | 18.04% |
| 5 | Pfizer | 159.20 Bn | 147.50 Bn | 10.94 Bn | 39.10% |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | 56.97% |
| 7 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 8 | Incyte | 25.50 Bn | 20.96 Bn | 1.57 Bn | 18.31% |
| 9 | United Therapeutics | 21.54 Bn | 18.88 Bn | 683.80 Mn | 43.42% |
| 10 | BeOne Medicines | 2.48 Bn | -2.62 Bn | 1.53 Bn | 52.90% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 52.90% |
| Mar 31, 2026 | 33.08% |
| Dec 31, 2025 | 49.06% |
| Sep 30, 2025 | 39.53% |
| Jun 30, 2025 | 39.14% |
| Mar 31, 2025 | 29.79% |
| Dec 31, 2024 | 29.03% |
| Sep 30, 2024 | 33.51% |
| Jun 30, 2024 | 38.96% |
| Mar 31, 2024 | -64.69% |
| Dec 31, 2023 | 12.63% |
| Sep 30, 2023 | 39.11% |
| Jun 30, 2023 | -3.78% |
| Mar 31, 2023 | -18.14% |
| Dec 31, 2022 | -6.00% |
| Sep 30, 2022 | -28.47% |
| Jun 30, 2022 | -102.00% |
| Mar 31, 2022 | -11.21% |
| Dec 31, 2021 | -37.84% |
| Sep 30, 2021 | -55.36% |